This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wada, S. Articles by Tahara, H. Search for Related Content PubMed PubMed Citation Articles by Wada, S. Articles by Tahara, H.

Rationale for Antiangiogenic Cancer Therapy with Vaccination Using Epitope Peptides Derived from Human Vascular Endothelial Growth Factor Receptor 2

¹ Department of Surgery and Bioengineering, Advanced Clinical Research Center and ² Department of Genetics and Clinical Oncology, Institute of Medical Science, University of Tokyo, Tokyo, Japan; ³ Department of Pathology, Vanderbilt University Medical Center, Nashville, Tennessee; and ⁴ Department of General Surgical Science, Gunma University, Gunma, Japan

Requests for reprints: Hideaki Tahara, Department of Surgery and Bioengineering, Advanced Clinical Research Center, Institute of Medical Science, University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108-8639, Japan. Phone: 81-3-5449-5582; Fax: 81-3-3446-2459; E-mail: tahara{at}ims.u-tokyo.ac.jp.

Angiogenesis is a critical mechanism for tumor progression. Multiple studies have suggested that tumor growth can be suppressed if tumor angiogenesis can be inhibited using various types of antiangiogenic agents. Recent studies in mouse systems have shown that tumor angiogenesis can also be inhibited if cellular immune response could be induced against vascular endothelial growth factor receptor 2 (VEGFR2), which is one of the key factors in tumor angiogenesis. In this study, we examined the possibility of developing this novel immunotherapy in clinical setting. We first identified the epitope peptides of VEGFR2 and showed that stimulation using these peptides induces CTLs with potent cytotoxicity in the HLA class I–restricted fashion against not only peptide-pulsed target cells but also endothelial cells endogenously expressing VEGFR2. In A2/Kb transgenic mice that express 1 and 2 domains of human HLA-A*0201, vaccination using these epitope peptides in vivo was associated with significant suppression of the tumor growth and prolongation of the animal survival without fatal adverse effects. In antiangiogenesis assay, tumor-induced angiogenesis was significantly suppressed with the vaccination using these epitope peptides. Furthermore, CTLs specific to the epitope peptides were successfully induced in cancer patients, and the specificities of the CTLs were confirmed using functional and HLA-tetramer analysis. These results in vitro and in vivo strongly suggest that the epitope peptides derived from VEGFR2 could be used as the agents for antiangiogenic immunotherapy against cancer in clinical settings.

This article has been cited by other articles:

				H. Komita, X. Zhao, J. L. Taylor, L. J. Sparvero, A. A. Amoscato, S. Alber, S. C. Watkins, A. D. Pardee, A. K. Wesa, and W. J. Storkus CD8+ T-Cell Responses against Hemoglobin-{beta} Prevent Solid Tumor Growth Cancer Res., October 1, 2008; 68(19): 8076 - 8084. [Abstract] [Full Text] [PDF]

				Y. Sun, M. Song, E. Jager, C. Schwer, S. Stevanovic, S. Flindt, J. Karbach, X. D. Nguyen, D. Schadendorf, and K. Cichutek Human CD4+ T Lymphocytes Recognize a Vascular Endothelial Growth Factor Receptor-2-Derived Epitope in Association with HLA-DR Clin. Cancer Res., July 1, 2008; 14(13): 4306 - 4315. [Abstract] [Full Text] [PDF]

				H. Takahashi, H. Ishizaki, H. Tahara, Y. Tamaki, and Y. Yanagi Suppression of Choroidal Neovascularization by Vaccination with Epitope Peptide Derived from Human VEGF Receptor 2 in an Animal Model Invest. Ophthalmol. Vis. Sci., May 1, 2008; 49(5): 2143 - 2147. [Abstract] [Full Text] [PDF]

				H. Mochimaru, T. Usui, T. Yaguchi, Y. Nagahama, G. Hasegawa, Y. Usui, S. Shimmura, K. Tsubota, S. Amano, Y. Kawakami, et al. Suppression of Alkali Burn-Induced Corneal Neovascularization by Dendritic Cell Vaccination Targeting VEGF Receptor 2 Invest. Ophthalmol. Vis. Sci., May 1, 2008; 49(5): 2172 - 2177. [Abstract] [Full Text] [PDF]

				H. Mochimaru, N. Nagai, G. Hasegawa, C. Kudo-Saito, T. Yaguchi, Y. Usui, T. Kurihara, T. Koto, S. Satofuka, H. Shinoda, et al. Suppression of Choroidal Neovascularization by Dendritic Cell Vaccination Targeting VEGFR2 Invest. Ophthalmol. Vis. Sci., October 1, 2007; 48(10): 4795 - 4801. [Abstract] [Full Text] [PDF]

				H. Ishizaki, T. Tsunoda, S. Wada, M. Yamauchi, M. Shibuya, and H. Tahara Inhibition of tumor growth with antiangiogenic cancer vaccine using epitope peptides derived from human vascular endothelial growth factor receptor 1. Clin. Cancer Res., October 1, 2006; 12(19): 5841 - 5849. [Abstract] [Full Text] [PDF]

				B. Kim, S. Suvas, P. P. Sarangi, S. Lee, R. A. Reisfeld, and B. T. Rouse Vascular Endothelial Growth Factor Receptor 2-Based DNA Immunization Delays Development of Herpetic Stromal Keratitis by Antiangiogenic Effects J. Immunol., September 15, 2006; 177(6): 4122 - 4131. [Abstract] [Full Text] [PDF]